+223.1%
BMNR vs MRNA
+430.5%
-207.4%
-90.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.4% | +5.4% | -2.0% | +2.8% |
| 7D | +0.2% | -1.1% | +1.3% | +0.4% |
| 30D | +39.9% | +126.1% | -86.2% | +16.5% |
| 3M | +51.5% | +190.0% | -138.5% | +5.9% |
| 6M | +18.9% | +157.2% | -138.3% | -11.4% |
| YTD | -7.8% | +388.2% | -396.0% | -57.6% |
| 1Y | -47.6% | +467.0% | -514.6% | -80.9% |
| All | +223.1% | +430.5% | -207.4% | -56.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling